Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Frequently asked questions
What sector does Editas Medicine, Inc.ORD SHS (EDIT-RM) operate in?
Editas Medicine, Inc.ORD SHS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Editas Medicine, Inc.ORD SHS (EDIT-RM) current stock price?
As of the latest data, Editas Medicine, Inc.ORD SHS stock price is RUB 53.00, with a previous close of RUB 53.00.
What is Editas Medicine, Inc.ORD SHS (EDIT-RM) current market capitalization?
Editas Medicine, Inc.ORD SHS market cap is approximately 417.74 million.
What is Editas Medicine, Inc.ORD SHS (EDIT-RM) Earnings Per Share (EPS)?
The trailing EPS is -RUB 142.03, and the forward EPS is -RUB 0.75.
What is Editas Medicine, Inc.ORD SHS (EDIT-RM) EBITDA?
Editas Medicine, Inc.ORD SHS EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -1.54 billion.
Does Editas Medicine, Inc.ORD SHS (EDIT-RM) pay dividends?
No. Editas Medicine, Inc.ORD SHS does not pay a dividend.
How did Editas Medicine, Inc.ORD SHS (EDIT-RM) perform in its most recent earnings report?
In the last report (June 30, 2026), Editas Medicine, Inc.ORD SHS posted an EPS surprise of 50% and a revenue surprise of 33,923.8%.
When is Editas Medicine, Inc.ORD SHS (EDIT-RM) next earnings report?
Editas Medicine, Inc.ORD SHS is expected to release its next earnings report on September 30, 2026.
What is Editas Medicine, Inc.ORD SHS (EDIT-RM) beta (volatility) score?
Editas Medicine, Inc.ORD SHS has a beta of -0.085, indicating lower volatility than the overall market.
